ClinicalTrials.gov
public full text
Public Domain
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia#1337106
- To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma#1339217
- Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia#1244137
- A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia#1075080
- Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia#1093121
Record · ID 1262736
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive